Clinical Trial Detail

NCT ID NCT03079687
Title Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Recruitment Approved for marketing
Gender
Phase Expanded access
Variant Requirements No
Sponsors AstraZeneca
Indications

peritoneal carcinoma

ovary epithelial cancer

fallopian tube cancer

Therapies

Olaparib

Age Groups:

No variant requirements are available.